GlassScriptPhysician profile
Ashley Pajk
NPI 1679124291
$3,878.61
in general payments reported to CMS, 2019-2025
24 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $1,117 · 2023: $1,419 · 2024: $722 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,372.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $963.37 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $806.79 | 2021-2025 | |
| Glaxosmithkline, LLC. | $285.83 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $228.26 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.87 | 2021-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $200.67 | 2022-2024 | Mounjaro, Amyvid, Jardiance |
| Amgen INC. | $200.59 | 2021-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $151.08 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $143.09 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $110.65 | 2022-2025 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Novartis Pharmaceuticals Corporation | $100.47 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $57.70 | 2021-2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $50.60 | 2021 | |
| Astellas Pharma US INC | $48.02 | 2023-2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.32 | 2021-2024 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $37.17 | 2024 | |
| Avanir Pharmaceuticals, INC. | $28.08 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.08 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $25.73 | 2023 | Auvelity |
| Insulet Corporation | $25.35 | 2022 | |
| Amarin Pharma, INC. | $20.57 | 2021 | |
| Corcept Therapeutics | $19.27 | 2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $15.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Pajk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.